An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
WASHINGTON--(BUSINESS WIRE)--
This week, the Association of Clinical Research Organizations (ACRO)’s RBQM Working Group published a paper in DIA’s Therapeutic Innovation & Regulatory Science journal titled, Risk-Based Monitoring in Clinical Trials: 2021 Update.
For the past three years, ACRO’s RBQM Working Group has conducted an annual landscape survey of member company CROs to determine how remote monitoring and risk-based quality management processes are being implemented across the industry. The group looked at adoption rates of remote monitoring, quality tolerance limits (QTLs), centralized monitoring, and several other components. This paper details the latest findings, drawing on collected data on 5,000+ ongoing clinical trials for each of the past three years.
ACRO’s first survey project started the year prior to the COVID-19 pandemic. As a result, the subsequent two years provide a unique perspective on how adoption rates of remote- and risk-based approaches have changed and evolved through the pandemic, and over time.
“The ACRO team worked together to gather this data for a third consecutive year, and we believe it’s telling in how clinical trials are currently being operationalized and will be run in the years to come,” said the RBQM Working Group’s lead, Brian Barnes, RBQM Strategy Specialist at Medidata Solutions.
With the continued impact of the pandemic on how clinical trials are designed and executed and the increasing number of partially or fully decentralized clinical trials (DCTs), ACRO’s RBQM Working Group expects these adoption rates to continue to increase over time.
By sharing this data, the CROs and technology providers of ACRO hope to continue collaborating across all stakeholders, from ACRO members, to sponsors and regulators to make collective progress towards advancing how clinical trials are conducted most effectively and efficiently.
The Association of Clinical Research Organizations (ACRO) represents clinical research and technology companies that provide a variety of specialized services to support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO helps improve the quality, efficiency, and safety of biomedical research. ACRO member companies operate in more than 100 countries across the globe and conduct or support the conduct of the majority of industry-sponsored clinical trials worldwide.
dassault systèmes, the 3dexperience company, provides business and people with virtual universes to imagine sustainable innovations. its world-leading solutions transform the way products are designed, produced, and supported. dassault systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. the group brings value to over 220,000 customers of all sizes, in all industries, in more than 140 countries. for more information, visit www.3ds.com. 3dexperience, the compass logo, 3ds logo, catia, solidworks, enovia, delmia, simulia, geovia, exalead, 3d via, biovia, netvibes, 3dexcite are registered trademarks of dassault systèmes or its subsidiaries in the us and/or other countries.
